Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

Prior treatment

• Has a cranial implant (with the exception of dental implants), neurostimulator, implanted medication pump, spinal cord stimulator, or pacemaker/implantable cardioverter-defibrillator
• Has knowledge of planned magnetic resonance imaging (MRIs) in the next 12 months, after implant
• In the opinion of the investigator, the implant and therapy pose an unacceptable surgical or medical risk to the patient
• Is currently taking blood thinners and cannot be taken off blood thinners
• Currently taking medication that would alter the seizure threshold, increasing potential seizure risks
• Has failed all attempts to achieve at least 50% reduction in depressive symptoms after completion of approved treatment courses of electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) for treatment of MDD
• Is planning to receive any other neuromodulation therapy during the study
• Meets the DSM-5 criteria for alcohol use disorder or other substance use disorder (not including tobacco/nicotine) within 12 months prior to study enrollment or, in the opinion of the investigator, is using illicit drugs recreationally or therapeutically which could impact the safety or effectiveness of the therapy
• In the investigator's opinion, any known comorbidity that would complicate the assessment of safety or prevent participation in follow-up visits
  • Before implantation of the Motif Digitally Programmable Over-Brain Therapeutic (DOT) Implant, subjects must continue to meet all study eligibility criteria. Subjects must also meet the following additional criteria:
• Has skull thickness ≥5.5 mm and ≤15.5 mm over the implant target

Other illness

• Has taken hallucinogenic or dissociative medications in the past 30 days or is planning on taking hallucinogenic or dissociative medications for the treatment of mood or anxiety disorders before the 4-week follow-up visit
• Has a history of bipolar disorder
• Has a history of schizophrenia, schizoaffective disorder, or other psychotic disorder
• Has a chronic and clinically significant neurological disorder (epilepsy, dementia, delirium, amnestic disorder, brain tumor), or neuroimaging findings that would potentially impact the efficacy of treatment (e.g., extensive white matter disease, demyelinating lesions, atrophy, brain tumor)
• Has a history of brain injury that resulted in current cognitive impairment
• Has a history of bony disorders that impact the safe and effective use of the device as well as device implantation
• Has a history of skin disorders that impact the safe and effective use of the device as well as device implantation
• Psychiatric treatment regimen has remained stable

Other

• Is unable to undergo imaging with computed tomography (CT), magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), or functional magnetic resonance imaging (fMRI)
• Has taken ketamine or esketamine in the past 30 days or is planning on taking ketamine or esketamine before the 4-week follow-up visit
• Has psychotic features in the current depressive episode
• Female who is pregnant at the time of inclusion, or planning to become pregnant during the duration of the study, or not willing to use an effective method of birth control
• Has a life expectancy less than 12 months
• In the opinion of the investigator, is considered to be acutely suicidal (e.g., Type 4 or 5 on the Columbia-Suicide Severity Rating Scale \[C-SSRS\])

• Has a diagnosis of unipolar non-psychotic Major Depressive Disorder (MDD) and is currently experiencing a major depressive episode (MDE) as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
• Has a screening Montgomery-Åsberg Depression Rating Scale (MADRS) score of ≥20
• Has not had a sustained response to 2 or more adequately dosed antidepressant treatments from at least 2 different antidepressant treatment classes in at least one episode of major depressive disorder, according to the Antidepressant Treatment History Form (ATHF)
• Is willing and able to provide written informed consent
• Is 22-85 years of age
• Is willing and able to comply with the protocol, including follow-up visits
• Has been on a stable psychiatric treatment regimen for 30 days before the study screening MADRS and is willing to maintain a stable psychiatric treatment regimen through the Week 4 follow-up visit